RU2015133046A - Двойной вектор для подавления вируса иммунодефицита человека - Google Patents
Двойной вектор для подавления вируса иммунодефицита человека Download PDFInfo
- Publication number
- RU2015133046A RU2015133046A RU2015133046A RU2015133046A RU2015133046A RU 2015133046 A RU2015133046 A RU 2015133046A RU 2015133046 A RU2015133046 A RU 2015133046A RU 2015133046 A RU2015133046 A RU 2015133046A RU 2015133046 A RU2015133046 A RU 2015133046A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- hiv
- promoter
- vector
- rna
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims 9
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 238000000034 method Methods 0.000 claims 23
- 239000004055 small Interfering RNA Substances 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108020004459 Small interfering RNA Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 5
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims 5
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 3
- 108091006086 inhibitor proteins Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 claims 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims 2
- 102000001493 Cyclophilins Human genes 0.000 claims 2
- 108010068682 Cyclophilins Proteins 0.000 claims 2
- 101000680666 Homo sapiens Tripartite motif-containing protein 5 Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102000009572 RNA Polymerase II Human genes 0.000 claims 2
- 108010009460 RNA Polymerase II Proteins 0.000 claims 2
- 102000014450 RNA Polymerase III Human genes 0.000 claims 2
- 108010078067 RNA Polymerase III Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000052612 human TRIM5 Human genes 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims 1
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims 1
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 1
- 101710130650 Tripartite motif-containing protein 5 Proteins 0.000 claims 1
- 102100022405 Tripartite motif-containing protein 5 Human genes 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 108010056354 Ubiquitin C Proteins 0.000 claims 1
- 229940123627 Viral replication inhibitor Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 108700035909 rhesus monkey TRIM5 Proteins 0.000 claims 1
- WIOOVJJJJQAZGJ-ISHQQBGZSA-N sifuvirtide Chemical compound C([C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CO)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 WIOOVJJJJQAZGJ-ISHQQBGZSA-N 0.000 claims 1
- 108010048106 sifuvirtide Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
Claims (25)
1. Способ получения вирусного экспрессионного вектора, который, присутствуя в клетке, может подавлять связывание ВИЧ с клеткой или предотвращать слияние ВИЧ с клеткой, который включает:
вставку первой молекулы нуклеиновой кислоты, кодирующей ингибирующую нуклеиновую кислоту, способную отрицательно регулировать экспрессию корецептора ВИЧ, в вектор; и
вставку второй молекулы нуклеиновой кислоты, кодирующей белок-ингибитор слияния ВИЧ, в вектор.
2. Способ по п. 1, в котором указанный вирусный экспрессионный вектор представляет собой лентивирусный вектор или ретровирусный вектор.
3. Способ по п. 2, в котором указанный лентивирусный вектор является самоинактивирующимся.
4. Способ по п. 2, в котором лентивирусный вектор представляет собой лентивирусный вектор FG11F.
5. Способ по любому из предшествующих пп., в котором белок-ингибитор слияния ВИЧ представляет собой белок С46, белок Т20, энфуфиртид, СР32М или сифувиртид.
6. Способ по п. 1, в котором ингибирующая нуклеиновая кислота представляет собой малую интерферирующую РНК (миРНК) или короткую шпилечную РНК (кшРНК), обладающую двухцепочечным участком.
7. Способ по п. 2, в котором ингибирующая нуклеиновая кислота является малой интерферирующей РНК (миРНК) или короткой шпилечной РНК (кшРНК), обладающая двухцепочечным участком.
8. Способ по п. 3, в котором ингибирующая нуклеиновая кислота является малой интерферирующей РНК (миРНК) или короткой шпилечной РНК (кшРНК), обладающая двухцепочечным участком.
9. Способ по п. 4, в котором ингибирующая нуклеиновая кислота является малой интерферирующей РНК (миРНК) или короткой шпилечной РНК (кшРНК), обладающей двухцепочечным участком.
10. Способ по п. 5, в котором ингибирующая нуклеиновая кислота является малой интерферирующей РНК (миРНК) или короткой шпилечной РНК (кшРНК), обладающей двухцепочечным участком.
11. Способ по п. 1, в котором указанный корецептор ВИЧ представляет собой CCR5 или CXCR4.
12. Способ по п. 2, в котором указанный корецептор ВИЧ представляет собой CCR5 или CXCR4.
13. Способ по п. 3, в котором указанный корецептор ВИЧ представляет собой CCR5 или CXCR4.
14. Способ по п. 4, в котором указанный корецептор ВИЧ представляет собой CCR5 или CXCR4.
15. Способ по п. 5, в котором указанный корецептор ВИЧ представляет собой CCR5 или CXCR4.
16. Способ по п. 11, в котором кшРНК имеет последовательность SEQ ID NO: 1.
17. Способ по п. 1, в котором белок-ингибитор слияния ВИЧ представляет собой белок С46 и тем, что ингибирующая нуклеиновая кислота представляет собой кшРНК, имеющую последовательность SEQ ID NO: 1.
18. Способ по п. 1, в котором первая последовательность нуклеиновых кислот функционально связана с первым промотором, а вторая последовательность нуклеиновых кислот функционально связана со вторым промотором.
19. Способ по п. 18, в котором указанный первый промотор является промотором РНК-полимеразы III, а указанный второй промотор является промотором РНК-полимеразы II.
20. Способ по п. 19, в котором промотор РНК-полимеразы III является промотором H1 полимеразы III.
21. Способ по п. 19, в котором промотор РНК-полимеразы II является промотором Убиквитин С полимеразы II.
22. Способ по п. 1, дополнительно включающий стадию вставки третьей молекулы нуклеиновой кислоты, которая кодирует ингибитор вирусной репликации ВИЧ в вектор.
23. Способ по п. 22, в котором ингибитор репликации ВИЧ выбирают из группы, содержащей: TRIM5α человека, TRIM5α макака-резус, химерный TRIM5α, белок слияния TRIM5 человека - циклофилин, циклофилин, Е3 убиквитин, APOBEC3G и антиген стромальных клеток костного мозга 2 (BST-2).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22568709P | 2009-07-15 | 2009-07-15 | |
US61/225,687 | 2009-07-15 | ||
US28759909P | 2009-12-17 | 2009-12-17 | |
US61/287,599 | 2009-12-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012105281/10A Division RU2562868C2 (ru) | 2009-07-15 | 2010-05-26 | Двойной вектор для подавления вируса иммунодефицита человека |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015133046A true RU2015133046A (ru) | 2018-12-24 |
Family
ID=42797105
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012105281/10A RU2562868C2 (ru) | 2009-07-15 | 2010-05-26 | Двойной вектор для подавления вируса иммунодефицита человека |
RU2015133046A RU2015133046A (ru) | 2009-07-15 | 2010-05-26 | Двойной вектор для подавления вируса иммунодефицита человека |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012105281/10A RU2562868C2 (ru) | 2009-07-15 | 2010-05-26 | Двойной вектор для подавления вируса иммунодефицита человека |
Country Status (10)
Country | Link |
---|---|
US (3) | US20120201794A1 (ru) |
EP (4) | EP2949208B1 (ru) |
JP (4) | JP5828838B2 (ru) |
AU (1) | AU2010274031B2 (ru) |
CA (1) | CA2767972A1 (ru) |
DK (2) | DK3329772T3 (ru) |
ES (3) | ES2770627T3 (ru) |
HK (1) | HK1168509A1 (ru) |
RU (2) | RU2562868C2 (ru) |
WO (1) | WO2011008348A2 (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
GB201012410D0 (en) * | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
AU2012275526A1 (en) * | 2011-06-29 | 2014-01-16 | Ronilu Development Corporation | Prevention and treatment of HIV infection |
AU2014296059B2 (en) * | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
EP4316500A3 (en) | 2015-05-13 | 2024-04-10 | CSL Behring Gene Therapy, Inc. | Bio-production of lentiviral vectors |
WO2016187151A1 (en) | 2015-05-18 | 2016-11-24 | Calimmune, Inc. | Methods of discriminating between hiv-1 and lentiviral vectors |
JP2018518196A (ja) * | 2015-05-18 | 2018-07-12 | カリミューン, インコーポレーティッド | Hivの治療のための遺伝子治療法およびその使用 |
WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
IL310925A (en) | 2016-01-15 | 2024-04-01 | American Gene Tech Int Inc | Methods and preparations for activating GAMMA-DELTA T cells |
US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
EP4036231A1 (en) | 2016-03-09 | 2022-08-03 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
CN105861559B (zh) * | 2016-04-11 | 2018-05-01 | 苏州奥特铭医药科技有限公司 | 一种能直接反应i型干扰素应答的慢病毒载体及其制备方法与应用 |
EP3458589A4 (en) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
CN106086075B (zh) * | 2016-06-23 | 2019-08-06 | 福建医科大学 | CXCR4RNAi慢病毒载体的构建方法 |
EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY |
US11583562B2 (en) | 2016-07-21 | 2023-02-21 | American Gene Technologies International Inc. | Viral vectors for treating Parkinson's disease |
BR112019014082A2 (pt) * | 2017-01-09 | 2020-03-03 | American Gene Technologies International Inc. | Imunoterapia para hiv sem etapa de pré-imunização |
CA3049980A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
JP2020516283A (ja) | 2017-04-11 | 2020-06-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒドロキシステロイド(17−ベータ)デヒドロゲナーゼ(hsd17b)ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | ハンチントン病治療組成物および方法 |
EP3655534A1 (en) | 2017-07-18 | 2020-05-27 | Calimmune, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
US20190269734A1 (en) * | 2017-11-15 | 2019-09-05 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
CN112703004A (zh) | 2018-07-15 | 2021-04-23 | 伊诺奇安生物制药公司 | 使用重组树突状细胞用于癌症治疗的方法和组合物 |
US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
CA3204357A1 (en) * | 2021-01-28 | 2022-08-04 | Todd LUMAN | Methods for transducing immune cells |
RU2768032C1 (ru) * | 2021-09-02 | 2022-03-23 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4 |
RU2769125C1 (ru) * | 2021-09-02 | 2022-03-28 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5 |
WO2023245011A2 (en) * | 2022-06-15 | 2023-12-21 | Cedars-Sinai Medical Center | Noncoding rna agents (bcyrn1 and derivatives thereof) to treat diseases of immunity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US7737124B2 (en) * | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
RU2324738C2 (ru) * | 2006-06-16 | 2008-05-20 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) | ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ НА ОСНОВЕ ВЕКТОРНОЙ ПЛАЗМИДЫ pEGFP-N1, ПРОДУЦИРУЮЩАЯ siPHK-ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА 1 ТИПА (ЕЕ ВАРИАНТЫ) |
CN101841399B (zh) * | 2009-03-16 | 2013-08-07 | 上海贝尔股份有限公司 | 多基站协作接收网络中实现同步上行harq进程的方法和装置 |
SI2770061T1 (sl) * | 2009-07-24 | 2019-02-28 | Immune Design Corp. | Neintegrirani lentiviralni vektorji |
-
2010
- 2010-05-26 WO PCT/US2010/036247 patent/WO2011008348A2/en active Application Filing
- 2010-05-26 CA CA2767972A patent/CA2767972A1/en not_active Abandoned
- 2010-05-26 EP EP15166660.9A patent/EP2949208B1/en not_active Not-in-force
- 2010-05-26 JP JP2012520638A patent/JP5828838B2/ja not_active Expired - Fee Related
- 2010-05-26 ES ES17197440T patent/ES2770627T3/es active Active
- 2010-05-26 ES ES10720980.1T patent/ES2546663T3/es active Active
- 2010-05-26 DK DK17197440.5T patent/DK3329772T3/da active
- 2010-05-26 RU RU2012105281/10A patent/RU2562868C2/ru active
- 2010-05-26 EP EP19198486.3A patent/EP3659435A1/en not_active Withdrawn
- 2010-05-26 ES ES15166660.9T patent/ES2657737T3/es active Active
- 2010-05-26 AU AU2010274031A patent/AU2010274031B2/en not_active Ceased
- 2010-05-26 EP EP10720980.1A patent/EP2453735B1/en active Active
- 2010-05-26 DK DK15166660.9T patent/DK2949208T3/en active
- 2010-05-26 US US13/384,206 patent/US20120201794A1/en not_active Abandoned
- 2010-05-26 EP EP17197440.5A patent/EP3329772B1/en active Active
- 2010-05-26 RU RU2015133046A patent/RU2015133046A/ru not_active Application Discontinuation
-
2012
- 2012-09-25 HK HK12109456.4A patent/HK1168509A1/xx not_active IP Right Cessation
-
2015
- 2015-08-21 JP JP2015163281A patent/JP6247259B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-09 US US15/150,373 patent/US20160243169A1/en not_active Abandoned
-
2017
- 2017-11-16 JP JP2017220978A patent/JP6529141B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-10 JP JP2019089588A patent/JP6840189B2/ja active Active
-
2021
- 2021-07-07 US US17/368,947 patent/US20220016176A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2949208B1 (en) | 2017-11-15 |
WO2011008348A2 (en) | 2011-01-20 |
US20120201794A1 (en) | 2012-08-09 |
JP2019122413A (ja) | 2019-07-25 |
CA2767972A1 (en) | 2011-01-20 |
EP2453735B1 (en) | 2015-07-08 |
EP2453735A2 (en) | 2012-05-23 |
JP5828838B2 (ja) | 2015-12-09 |
HK1168509A1 (en) | 2013-01-04 |
JP6529141B2 (ja) | 2019-06-12 |
EP3329772B1 (en) | 2019-10-16 |
US20220016176A1 (en) | 2022-01-20 |
EP3329772A1 (en) | 2018-06-06 |
JP2012533299A (ja) | 2012-12-27 |
RU2012105281A (ru) | 2013-08-20 |
ES2770627T3 (es) | 2020-07-02 |
RU2562868C2 (ru) | 2015-09-10 |
DK2949208T3 (en) | 2018-01-22 |
JP6840189B2 (ja) | 2021-03-10 |
ES2546663T3 (es) | 2015-09-25 |
EP3659435A1 (en) | 2020-06-03 |
JP6247259B2 (ja) | 2017-12-13 |
US20160243169A1 (en) | 2016-08-25 |
JP2016013128A (ja) | 2016-01-28 |
DK3329772T3 (da) | 2020-01-27 |
WO2011008348A3 (en) | 2011-03-10 |
ES2657737T3 (es) | 2018-03-06 |
JP2018050633A (ja) | 2018-04-05 |
AU2010274031B2 (en) | 2015-07-16 |
EP2949208A1 (en) | 2015-12-02 |
AU2010274031A1 (en) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015133046A (ru) | Двойной вектор для подавления вируса иммунодефицита человека | |
CN107502608B (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
JP4353945B2 (ja) | 効率的なdna逆位反復構造の調製方法 | |
RU2018122636A (ru) | Стабильные клеточные линии для продуцирования ретровирусов | |
RU2017117510A (ru) | Редактирование целевой рнк | |
Jain et al. | Distinct functions of argonaute slicer in siRNA maturation and heterochromatin formation | |
JP2011520424A5 (ru) | ||
CN103805635B (zh) | 一种基于J亚群禽白血病病毒env基因保守序列的siRNA重组干扰载体及其制备方法和应用 | |
RU2018118204A (ru) | Улучшенные эукариотические клетки для получения белка и способы их получения | |
US9469862B2 (en) | Modified polymerases for replication of threose nucleic acids | |
Dash et al. | Sequence-specific cleavage activities of DNA enzymes targeted against HIV-1 Gag and Nef regions | |
EP2007882B1 (fr) | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence | |
EP3516050B1 (en) | A mutant reverse transcriptase | |
CN111235150B (zh) | 用于抑制非洲猪瘟病毒复制的shRNA及其用途 | |
ES2396371T3 (es) | Oligonucleótidos contra la infección de VIH y su uso en la prevención y tratamiento del síndrome de inmunodeficiencia adquirida | |
JP5139067B2 (ja) | shRNA発現のための有効な新規ループ配列 | |
Zhang et al. | Therapeutic potential of RNA interference against cellular targets of HIV infection | |
Kyriakou et al. | The rRNA and tRNA transcripts of maternally and paternally inherited mitochondrial DNAs of Mytilus galloprovincialis suggest presence of a “degradosome” in mussel mitochondria and necessitate the re-annotation of the l-rRNA/CR boundary | |
CN103966259B (zh) | 一种基于J亚群禽白血病病毒gag基因保守序列的siRNA重组干扰载体及其制备方法和应用 | |
Salinas‐Giegé et al. | Cyanophora paradoxa mitochondrial tRNAs play a double game | |
CN101024668A (zh) | 用于预防与治疗艾滋病的双链小分子干扰核糖核酸及其组合 | |
Hu et al. | Inhibition of CD46 receptor by RNAi enhances cell resistance to BVDV infection. | |
JPWO2019199807A5 (ru) | ||
RU2525935C2 (ru) | Способ получения кассетных генетических конструкций, экспрессирующих несколько рнк-шпилек | |
JP5917722B2 (ja) | ヒト由来細胞の特異細胞の作製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180808 |